cRCT of AI Agent in Clinital Resoning Training
AI Clinical Reasoning Training Agent on Medical Students' Clinical Reasoning Skills and Case-based Learning Experience: A Cluster Randomized Controlled Trial
1 other identifier
interventional
88
1 country
1
Brief Summary
Traditional medical education has long emphasized one-way transmission of theoretical knowledge, which presents limitations in the systematic cultivation of clinical reasoning skills among medical students. Miller's pyramid of clinical competence emphasizes the gradual transformation from theoretical knowledge to clinical practice ability. Case-based learning (CBL), as a teaching method centered on real or simulated clinical cases, is a key strategy to address the above limitations. Artificial intelligence (AI)-assisted clinical reasoning training tools can overcome time and space constraints, and offer students repeatable, adaptive, and real-time feedback case training, thereby reinforcing the sustained role of CBL in clinical reasoning development. Currently, it still lacks high-quality evidence from randomized controlled trials on the impact of AI agents on medical students' clinical reasoning skills. This study plans to evaluate the impact of an AI clinical reasoning training agent on students' clinical reasoning training outcomes and CBL learning experience. Primary Objective: To evaluate the impact of the AI agent on student learning outcomes (course examination scores and clinical reasoning test scores). Secondary Objective: To investigate students' AI acceptance (perceived usefulness, perceived ease of use, satisfaction, and intention to use). This study adopts a two-arm parallel cluster randomized controlled trial design. The trial is designed and reported in accordance with the CONSORT statement. The study population will recruit Class of 2021 medical students (8-year program) from Peking Union Medical College and Class of 2020 medical students (8-year program) from Tsinghua University School of Medicine. Both cohorts are officially enrolled in the "Comprehensive Clinical Course" for the 2025-2026 academic year, have consistent foundational knowledge in basic medicine and diagnostics, and are in the phase of clinical medicine theory learning, not yet having entered clinical practice. Using PASS 2025 software, the sample size per arm for the cRCT is 39, with number of clusters per arm K=N/M =13, Considering a 10% attrition or exclusion rate, the target recruitment is 88 participants. Considering potential heterogeneity in baseline between students from the two schools, and possible contamination due to discussions among dormitory mates during the intervention, this study will adopt stratified cluster randomization, first stratifying by school, then using dormitory as the smallest randomization unit. Dormitories will be sorted by the random number, with the first half allocated to the intervention group and the second half to the control group. Participants' group assignment will be revealed via unique student ID only after baseline data collection and informed consent are completed. This study will select five topics from the "Comprehensive Clinical Course": "Infectious Diarrhea," "Viral Hepatitis," "Bloodstream Infection," "Infective Endocarditis," and "Central Nervous System Infection". Standardized cases will be provided by the teaching faculty, with two cases per topic, totaling 10 cases. These cases will be used to train AI agent. After class, the AI agent training tasks will be sent to the intervention group, and study materials will be distributed to the control group. Course examination scores and clinical reasoning test scores are the primary outcomes. AI technology acceptance including perceived usefulness, perceived ease of use, satisfaction, and intention to use are the secondary outcomes. This study has been approved by the Research Ethics Committee of Peking Union Medical College Hospital (Approval No.: I-26PJ0851).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2026
CompletedFirst Submitted
Initial submission to the registry
April 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 8, 2026
CompletedFirst Posted
Study publicly available on registry
June 3, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2026
ExpectedJune 3, 2026
June 1, 2026
1 month
April 22, 2026
June 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Course examination scores
The examination includes 8 of A1 multiple choice questions (MCQs), 8 of case summary MCQs, 2 of A3 case-cluster MCQs, 3 A4 case-series best-answer MCQs, and 1 of case analysis questions, with a total score of 25. All test questions are provided by the teaching faculty, covering core diseases from the five topics. The questions will reviewed by the same two senior clinical faculty members to ensure appropriate case selection and difficulty.
One week after the course
Clinical reasoning test score
The test is designed based on a case of infective endocarditis (IE) and is supposed to be accomplished in 30 min. There are five questions in total. Information and questions will be presented step by step, with a total score of 25.
One month after the course
Secondary Outcomes (1)
AI technology acceptance
Immediately after the clinical reasoning test
Study Arms (2)
intervention group (AI Agent)
EXPERIMENTALcontrol group (study materials)
EXPERIMENTALInterventions
Study materials including case information, questions, and answer keys
Eligibility Criteria
You may qualify if:
- full-time registered and enrolled in the "Comprehensive Clinical Course"
- signed informed consent, voluntary participation in this study and completion of relevant tests and questionnaires
You may not qualify if:
- · planned suspension of studies, withdrawal, or major transfer during the study period
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Related Publications (3)
Leyrat C, Eldridge S, Taljaard M, Hemming K. Practical considerations for sample size calculation for cluster randomized trials. J Epidemiol Popul Health. 2024 Feb;72(1):202198. doi: 10.1016/j.jeph.2024.202198. Epub 2024 Feb 13.
PMID: 38477482BACKGROUNDMiller GE. The assessment of clinical skills/competence/performance. Acad Med. 1990 Sep;65(9 Suppl):S63-7. doi: 10.1097/00001888-199009000-00045. No abstract available.
PMID: 2400509BACKGROUNDHopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123.
PMID: 40228833BACKGROUND
Related Links
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 22, 2026
First Posted
June 3, 2026
Study Start
April 1, 2026
Primary Completion
May 8, 2026
Study Completion (Estimated)
August 31, 2026
Last Updated
June 3, 2026
Record last verified: 2026-06